Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

We came across a bullish thesis on Vericel Corporation on R.Dennis’s Substack by OppCost. In this article, we will summarize ...

Here’s where it gets truly serious: these administrative hiccups aren’t just annoying; they’re literally a matter of life and ...

Tempus AI's 10% dip reveals an opportunity as Q2 estimates are poised to exceed expectations, fueled by strong deals and ...

Measles cases are rising. Here’s a deep dive into 6 key questions Experts tell C&EN whether the measles virus can mutate, how durable the vaccine is, and more ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CLICK HERE BEFORE AUGUST 12, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

The integration of artificial intelligence (AI) in the cardiovascular space, particularly in electrocardiography (ECG), is reshaping clinical workflows, enabling earlier disease detection and opening ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CLICK HERE BEFORE AUGUST 12, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Recent discussions on X about Tempus AI, Inc. (TEM) have been buzzing with reactions to the company's latest financial outlook and market movements. Many users have highlighted the firm's raised ...

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines.